Theratechnologies Brief: Announcing Preliminary Tolerability and Efficacy Data From Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients With Advanced Ovarian Cancer
Theratechnologies Brief: Announcing Preliminary Tolerability and Efficacy Data From Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients With Advanced Ovarian Cancer
Theratechnologies 簡介：宣佈針對晚期卵巢癌患者的 Sudocetaxel Zendusortide 第10億期劑量範圍試驗的初步耐受性和療效數據
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊